Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 13/20 | 0.43 |
| ▸ | IMPDH1 | P20839 | 3/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18375349 | 0.80 | LMNA (0.42) | IMPDH2IMPDH1AAK1ROCK2ROCK1 | |
| SCHEMBL21376047 | 0.79 | IMPDH2 (0.52) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL30930931 | 0.79 | IMPDH2 (0.46) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL24720275 | 0.79 | IMPDH2 (0.46) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL20150098 | 0.78 | AAK1 (0.46) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL24026459 | 0.77 | IMPDH2 (0.44) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL22280426 | 0.76 | IMPDH2 (0.46) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL27584280 | 0.72 | IMPDH2 (0.59) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7723821 | 0.71 | IMPDH2 (0.47) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL24026509 | 0.71 | PDK2 (0.41) | IMPDH2IMPDH1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| US-11220508-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11174265-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220508-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | IMPDH2 4304/4885IMPDH1 4433/4885AAK1 146/4885 |
| US-11174265-B2 | — | TYK2, JAK2, JAK1 | IMPDH2 4561/4885IMPDH1 4690/4885AAK1 212/4885 |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | IMPDH2 4304/4885IMPDH1 4433/4885AAK1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.